RenovoRx, Inc.
RNXT
$1.06
$0.000.00%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
5/6/2025
-
Business Wire
5/1/2025
-
GuruFocus
5/1/2025
-
GuruFocus
5/1/2025
-
Business Wire
4/29/2025
-
GuruFocus
4/29/2025
-
The Fly
4/29/2025
-
GuruFocus
4/29/2025
-
GuruFocus
4/29/2025
-
Business Wire
4/26/2025
-
TipRanks Financial Blog
4/18/2025
-
Zolmax
4/18/2025
-
MarketBeat
4/17/2025
-
Ticker Report
4/16/2025
-
GuruFocus
4/16/2025
-
TipRanks Financial Blog
4/16/2025
-
The Fly
4/16/2025
-
Business Wire
4/15/2025
-
MarketBeat
4/12/2025
-
Ticker Report
4/10/2025
-
MarketBeat
4/4/2025
-
GuruFocus
4/4/2025
-
Business Wire
4/2/2025
-
Ticker Report
4/2/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, April 1, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 284 4433
Address
2570 West El Camino Real
Mountain View, CA 94040
Mountain View, CA 94040
Country
Year Founded
Business Description
Sector
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment...
more